Abstract
Background Hospitalized patients with COVID-19 are at increased risk for thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown.
Objective To evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia.
Design, setting, and participants Randomized controlled, multicenter trial (PROTHROMCOVID) enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia.
Interventions Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) doses of tinzaparin during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge.
Measurements The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days.
Results Of the 311 subjects randomized, 300 were included in the analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]. The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (P= 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences.
Conclusions In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to increase benefit regarding the likelihood of thrombotic event, non-invasive ventilation or high-flow oxygen, or death.
Trial Registration ClinicalTrials.gov Identifier (NCT04730856).
Funding This independent research initiative was supported by Leo-Pharma; Tinzaparin was provided by Leo Pharma.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests:NMR reports consultant fees from Boehringer Ingelheim, Aspen and Bayer, lecture fees from Leo Pharma, Rovi, Sanofi, Bayer, Boehringer Ingelheim outside of the submitted work. JAHR reports consultancy fees from Janssen, Roche, Abbvie, Gilead, BMS/Celgene, Amgen, Takeda, Rovi, AstraZeneca, EusaPharm, Sanofi, Lilly member of Speaker?s Bureau from Janssen, Roche, Abbvie, Gilead, BMS/Celgene, Amgen, Takeda, AstraZeneca, Beigene, Lilly and he has received Research Support from BMS/Celgene, Janssen, Sanofi, all of them outside of this study. MPP reports participation in educational activities sponsored by Bayer, Sanofi, Rovi, Daiichi-- Sankyo. PDR: Consulting or Advisory Role: Boehringer, LEO Pharma, Ingelheim, Techdow Speakers? Bureau: Rovi, Menarini, Sanofi, Gilead, Bayer, Boehringer, LEO Pharma, Aspen and Pfizer. ARG: reports lectures fees from ROVI, Leo Pharma y SANOFI. OMC: reports lecture fees from Sanofi, Rovi, Leo pharma JA. reports speaking fees from Daiichi Sankyo, Leo Pharma and Sanofi-Aventis. MMB reports lectures fees from ROVI, Bayer, Boehringer Ingelheim, Pfizer and Daiichi-Sankyo. All other authors declare no competing interests.
Clinical Trial
ClinicalTrials.gov Identifier (NCT04730856).
Funding Statement
This independent research initiative was supported by Leo-Pharma Tinzaparin was provided by Leo Pharma.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Foundation for Biomedical Research and Innovation of the Infanta Leonor University Hospital and the Southeast University Hospital sponsored the study. The trial was conducted in accordance with the Declaration of Helsinki and local regulatory requirements. The protocol was approved by the Ethical Committees for Drug Research at the Gregorio Marañón General University Hospital and, subsequently, by the local Drug Research Ethics Committees and the Spanish Agency for Medicines and Health Products. All patients included signed written informed consent forms.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
juan.torresm{at}salud.madrid.org
Data Availability
All relevant data are within the manuscript and its Supporting Information files. The data underlying the results presented in the study are available from https://prothromcovid.org/